Docoh
Loading...

Tue. 16 Nov 2021, 8:08am ETBenzinga
In: News, Price Target, Analyst Ratings
JMP Securities analyst Silvan Tuerkcan maintains LogicBio Therapeutics (NASDAQ:LOGC) with a Market Outperform and lowers the price target from $17 to $16.